BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 26 November, 2014 at 1.30 p.m. BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR SELINCRO® Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology assessment authority, has issued its final guidance for Selincro (nalmefene), recommending its use within the conditions of its marketing authorization in the National Health Service (NHS) in England and Wales as an option for reducing alcohol consumption for people with alcohol dependence. Upon issuance of the final guidance, the NHS has three months to implement the recommendation and make the necessary funding available. It is expected that up to 600,000 alcohol dependent individuals in England and Wales may be eligible for the treatment. Selincro (nalmefene) is a dual-acting opioid system modulator and the first therapy approved in Europe for the reduction of alcohol consumption in alcohol dependent individuals. Biotie has licensed global rights to Selincro to H.Lundbeck A/S (Lundbeck). Lundbeck received European marketing authorization for Selincro in February 2013 and has to date introduced the product in well over 20 European markets. Timo Veromaa, President and CEO of Biotie commented, "We are pleased that Selincro will now be available through the NHS to appropriate alcohol dependent patients in England and Wales. Positive reimbursement decisions have also been granted in a number of additional EU countries, including France and Spain, and our partner Lundbeck is continuing with its negotiations in order to provide access to this exciting new treatment option for patients." Turku, 26 November 2014 Biotie Therapies Corp. Timo Veromaa President and CEO Further information: For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main media www.biotie.com ABOUT SELINCRO® (NALMEFENE) Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (>60 g/day for men, >40 g/day for women) without physical withdrawal symptoms and who do not require immediate detoxification. Selincro should be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and the reduction of alcohol consumption. Treatment should be initiated only in patients who continue to have a high drinking risk level two weeks after an initial assessment. Selincro is to be taken as-needed; that is, on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. Biotie has licensed global rights to nalmefene to Lundbeck. Under the terms of the agreement, Biotie is eligible for up to EUR 89 million in upfront and milestone payments plus royalties on sales of nalmefene. To date, Biotie has received EUR 22 million in milestone payments from Lundbeck. Further potential milestone payments are expected on launches in certain ex-EU markets and if the product reaches certain predetermined sales. In addition, Biotie will continue to receive royalties on sales in all launched markets and make a contribution to Lundbeck towards post approval commitments studies. Lundbeck is responsible for the registration, manufacturing and marketing of the product. ABOUT BIOTIE Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and three additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, cocaine dependence, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. [HUG#1874409]
BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR
Top 10 Most Recent News Articles
Implantica's U.S. Launch Arrives With Cash Still to Burn
RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...
Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury
Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...
Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy
A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...
Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit
A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...
Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps
Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....
Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap
Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...
Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check
A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....
Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test
Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...
Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead
A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...
Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth
A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...
Continue ReadingTop 5 Most Recently Viewed Articles
DallasNews Shareholders Urged to Support Merger Deal with Hearst
Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...
Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained
Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....
Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering
Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...
Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook
Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....
Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation
Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...
Continue Reading